Molika Ashford covers personalized medicine and molecular diagnostics for GenomeWeb.
The company plans to make its PRS offering, currently used only in those who test negative for gene mutations, an option for all customers of European ancestry.
Foundation Medicine's ctDNA assay was able to subclassify patients into higher and lower recurrence risk groups with CTCs providing an additional boost.
In two trials in the neoadjuvant setting reported at SABCS, one showed improved rates of pathologic complete response with added immunotherapy, and the other showed no difference.
Clonal hematopoiesis variants appear to outnumber tumor mutations in the plasma of most cancer patients, the investigators found in their study.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.
The company is hoping that the comprehensive solution will help bring on more pharma customers and offer extended opportunities for current users.
In a survey conducted by an association working group, 40 percent of respondents said they are already offering TMB, with most others planning to do the same within the year.
Frederick National Lab and Q2 Solutions have been validating the kit as early users and plan to implement it in their clinical trial services.
The research-use-only system, which has a list price of $299,000, fits with Thermo Fisher's vision of a future of disseminated implementation of NGS.
The company plans to market its GeoMx instruments for broader, more discovery-oriented research with a sequencing-based readout.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.